When multiple myeloma comes back or stops responding to treatment, options can run out. An early clinical trial tested a new two-drug approach for this exact situation. The trial involved 56 patients and looked at a new antibody called WVT078, both by itself and paired with another drug called WHG626.
The main goal was to see if the treatments were safe and to find the right doses. On the activity side, the antibody alone led to a response in about 27% of patients. When combined with the second drug, that number rose to about 48%. More patients also achieved a complete response with the combination. The most common side effect was cytokine release syndrome, a known immune system reaction, and seven patients experienced dose-limiting toxicities.
It’s crucial to remember this is very early data from a Phase 1 study. The researchers haven’t yet settled on the recommended doses for further testing, and the trial wasn’t designed to prove which treatment is better. The results are a preliminary signal that needs much more investigation in larger groups of patients.